JPRN-UMIN000002953已完成2 期
Pharmacokinetic, pharmacodynamic and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer - Pharmacokinetic, pharmacodynamic and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer
ational Hospital Organization Kinki-Chuo Chest Medical Center0 个研究点目标入组 20 人开始时间: 2009年12月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Comorbidity of interstitial lung disease, severe pneumoconiosis, or severe chronic obstructive lung diseases. 2)Other uncontrolled comorbid diseases.
研究者
相似试验
进行中（未招募）
1 期
Phase II study with pharmacokinetic and pharmacodynamic evaluations of metronomic chemotherapy with oral Vinorelbine and Dexamethasone in advanced castraction-resistant prostate cancer patients - ProMet-3EUCTR2009-015116-17-ITARCO
已完成
1 期
A clinical study to evaluate the Pharmacokinetic and Pharmacodynamic properties of Darbepoetin alfa Injection, Hetero and â??ARANESP®â?? (Darbepoetin alfa Injection, Amgen), in Healthy Adult Human SubjectsCTRI/2016/03/006727Hetero Drugs Limited52
进行中（未招募）
不适用
A Phase I-II Pharmacokinetic/Pharmacodynamic Study of Replagal to Assess the Effects of Alternative Dose and Regimen in Patients with Fabry Disease (TKT027) - TKT027Fabry DiseaseEUCTR2004-000772-14-CZTKT Inc20
已完成
2 期
A Phase II Study of MR19A13A.JPRN-jRCT2051220112obuyo Oya12
已完成
2 期
Phase II study to evaluate pharmacodynamics, pharmacokinetics and safety after cyclic dose or continuous dose of FSN-013 for 3 cycles in Japanese healthy adult female subjectsdysmenorrheaJPRN-jRCT2080223983Fuji Pharma Co., Ltd.60